Abstract：Esophageal cancer is a common malignant tumor of digestive system in China. Concurrent chemoradiotherapy has become the widely recognized method for the treatment of inoperable locally advanced esophageal carcinoma. Nevertheless, clinical efficacy of concurrent chemoradiotherapy remains to be enhanced. Nimotuzumab, the first human monoclonal antibody to treat malignant tumors in China, has been applied in the treatment of nasopharyngeal carcinoma, glioma, pancreatic cancer and other malignant tumors, which yields significant survival benefits and causes mild adverse events. Hence, more and more scholars are paying attention to its application value in the treatment of esophageal cancer. In this article, research progress on the application of nimotuzumab in esophageal cancer was reviewed, aiming to provide new ideas for the treatment of esophageal cancer.
Jin Xiaoqian,Wang Lan,Han Chun. Research progress on application of nimotuzumab in esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 739-743.
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492. [2] Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma:chemotherapy, molecular-targeting therapy and immunotherapy[J]. Jpn J Clin Oncol, 2019, 49(5):412-420. DOI:10.1093/jjco/hyz034. [3] Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials[J]. Front Oncol, 2014, 4:244. DOI:10.3389/fonc.2014.00244. [4] Kani K, Warren CM, Kaddis CS, et al. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin[J]. J Biol Chem, 2005, 280(9):8238-8247. DOI:10.1074/jbc. M410944200. [5] Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin[J]. MAbs, 2009, 1(1):41-48. DOI:10.4161/mabs.1.1.7509. [6] 邱倩,倪旭东,熊玮. 西妥昔单抗治疗非小细胞肺癌耐药机制的研究进展[J]. 中华肿瘤防治杂志,2010, 17(20):1683-1687. Qiu Q, Ni XD, Xiong W. Research progress of resistance mechanisms in the treatment of non-small cell lung cancer with cetuximab[J]. Chin J Cancer Prev Treat, 2010, 17(20):1683-1687. [7] You R, Sun R, HuaY J, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage Ⅱ-ⅣB nasopharyngeal carcinoma[J]. Int J Cancer, 2017, 141(6):1265-1276. DOI:10.1002/ijc.30819. [8] Setty K, Babu G. BIOMAb EGFRTM (Nimotuzumab) in combination with the standard of care in squamous cell carcinoma of the head and neck (SCCHN)[J]. J Thorac Oncol, 2006, 1(8):920. [9] Song H, Pan B, Yi J, et al. Featured article:autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma[J]. Exp Biol Med (May wood), 2014, 239(5):529-541. DOI:10.1177/15353702145 25315. [10] Li JC, Wang LH, Qiu ZD, et al. Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line[J]. Oncol Lett, 2019, 17(3):2763-2769. DOI:10.3892/ol.2019.9897. [11] Zhao KL, Hu XC, Wu XH, et al. A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus[J]. Invest New Drugs, 2012, 30(4):1585-1590. DOI:10.1007/s10637-011-9735-0. [12] Wang CY, Fu XL, Cai XW, et al. High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy[J]. Oncol Targets Ther, 2016, 9:117-122. DOI:10.2147/OTT. S89592. [13] Kato K, Ura T, Koizumi W, et al. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer:A phase I study[J]. Cancer Sci, 2018, 109(3):785-793. DOI:10.1111/cas.13481. [14] Zhu JH, Zhao WX, Liang D, et al. Risk of fatigue in cancer patients receiving antI-EGFRmonoclonal antibodies:results from a systematic review and meta-analysis of randomized controlled trial[J]. Int J Clin Oncol, 2018, 23(2):389-399. DOI:10.1007/s10147-017-1218-7. [15] Li J, Yan HX. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients:a meta-analysis of 65 randomized controlled trials[J]. Cancer Chemother Pharmacol, 2018, 82(4):571-583. DOI:10.1007/s00280-018-3644-2. [16] Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J]. Cancer Biol Ther, 2012, 13(8):600-605. DOI:10.4161/cbt.19849. [17] Saumell Y, Sanchez L, González S, et al. Overall survival of patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with nimotuzumab in the real world[J]. Adv Ther, 2017, 34(12):2638-2647. DOI:10.1007/s12325-017-0631-7. [18] de Castro-Junior G, Segalla JG, de Azevedo SJ, et al. A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer:NICE trial[J]. Eur J Cancer, 2018, 88:21-30. DOI:10.1016/j.ejca.2017.10.005. [19] 侯小霞,常志伟,秦艳茹. 尼妥珠单抗联合紫杉醇脂质体、顺铂同步放化疗治疗晚期食管癌的效果[J]. 河南医学研究,2019, 28(12):2144-2147. DOI:10.3969/j.issn.1004-437X.2019.12.010. Hou XX, Chang ZW, Qin YR. The effect observation of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of advanced esophageal carcinoma[J]. Henan Med Res, 2019, 28(12):2144-2147. DOI:10.3969/j.issn.1004-437X.2019.12.010. [20] Wang L, Liang J, Li N, et al. Evaluation of nimotuzumab combined with radiotherapy on esophageal carcinoma:a phase Ⅱ clinical trial[J]. J Clin Oncol, 2011, 29(15):2696-2696. DOI:10.1093/annonc/mdr431. [21] Lu M, Wang XC, Shen L, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer:a single centre prospective phase Ⅱ trial[J]. Cancer Sci, 2016, 107(4):486-490. DOI:10.1111/cas.12894. [22] Zhang XD, Jia J, Lu M, et al. Nimotuzumab plus paclitaxel and cisplatin as a 1st-Line treatment for esophageal cancer:Long term follow-up of a phase Ⅱ study[J]. J Cancer, 2019, 10(6):1409-1416. DOI:10.7150/jca.28659. [23] Han XH, Lu NN, Pan YY, et al. Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer[J]. Med Sci Monit, 2017, 23:412-418. DOI:10.12659/msm.902645. [24] 吴小源,邢文群,李雪,等. 尼妥珠单抗联合术前同期放化疗治疗局部进展期食管鳞癌初步临床研究[J]. 中华放射肿瘤学杂志,2019, 28(3):185-187. DOI:10.3760/cma.j.issn.1004-4221.2019.03.005. Wu XY, Xing WQ, Li X, et al. Preliminary clinical study of Nituzumab combined with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Chin J Radiat Oncol, 2019, 28(3):185-187. DOI:10.3760/cma.j.issn.1004-4221.2019.03.005. [25] Qi SC, Mao Y, Jiang MJ. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer[J]. Cancer Chemother Pharmacol, 2019, 84(5):1115-1123. DOI:10.1007/s00280-019-03944-w. [26] Chen YS, Wu XY, Hao DX, et al. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma[J]. Oncotarget, 2019, 10(40):4069-4078. DOI:10.18632/oncotarget.23861. [27] Jing W, Yan WW, Liu YG, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma[J]. Cancer Biol Ther, 2019, 20(8):1121-1126. DOI:10.1080/15384 047.2019.1598760. [28] Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus[J]. Int J Cancer, 2006, 118(5):1173-1180. DOI:10.1002/ijc.21454. [29] Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer[J]. Br J Cancer, 2005, 93(1):107-115. DOI:10.1038/sj.bjc.6602625. [30] Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas:association with poor outcome[J]. Cancer, 2007, 109(4):658-667. DOI:10.1002/cncr.22445. [31] Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification[J]. Cancer, 1994, 74(3):795-804. DOI:10.1002/1097-0142(19940801)74:3<795::aid-cncr2820740303>3.0.co;2-i. [32] Jia J, Cui Y, Lu M, et al. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma[J]. Clin Transl Oncol, 2016, 18(6):592-598. DOI:10.1007/s12094-015-1406-8. [33] Pühringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett′s) adenocarcinomas[J]. Dis Esophagus, 2007, 20(1):9-11. DOI:10.1111/j.1442-2050.2007.00630.x. [34] Sunpaweravong P, Suwiwat S, Sunpaweravong S, et al. Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma[J]. J Med Assoc Thai, 2009, 92(9):1136-1142. [35] Maeng CH, Lee J, van Hummelen P, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations[J/OL]. PLoS One, 2012, 7(8):e41655. DOI:10.1371/journal.pone.0041655. [36] Wang CY, Deng JY, Cai XW, et al. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients:preliminary clinical result and testable hypothesis[J]. Oncotarget, 2015, 6(21):18674-18682. DOI:10.18632/oncotarget.4367.
2021, Vol. 30 
